Dihydroergotamine (mesylate)
CAS No. : 6190-39-2
| Size | Price | Stock |
|---|---|---|
| 5mg | $32 | In-stock |
| 10mg | $50 | In-stock |
| 25mg | $60 | In-stock |
| 50mg | $70 | In-stock |
| 100mg | $105 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-B0670A |
| M.Wt: | 679.78 |
| Formula: | C34H41N5O8S |
| Purity: | >98 % |
| Solubility: | DMSO : 50 mg/mL (ultrasonic) |
Dihydroergotamine mesylate is an ergot alkaloid that can be used for the research of migraines[1][2][3].
In Vitro:Dihydroergotamine (10 μM, 72 h) reduces cell survival in A549 and NCI-H226 cells[4].
Dihydroergotamine (48 h) inhibits cell survival in Hep3B, PLC/PRF/5, Huh7 and HepG2 cells with IC50s of 49.91 μM, 42.0 μM, 25.42 μM and 20.23 μM respectively[5].
Dihydroergotamine (10 μM, 72 h) induces mitochondrial morphologic alterations and dysfunction, increases
ROS generation, induces apoptosis, and disturbs ATP production. in A549 cells[4].
Dihydroergotamine (40 μM, 48 h) inhibits STAT3 activation (down-regulates p-STAT3, while increasing p-ERK and has no effect on p-AKT), and enhances the protein stability of Mcl-1 (increases total p-Mcl-1 (Thr163) and Mcl-1) in HepG2 and Huh7 cells[5].
In Vivo:Dihydroergotamine mesylate (oral gavage, 44 mg/kg) combined with Sorafenib (HY-10201) (oral gavage, 30 mg/kg) inhibits tumor growth of liver cancer in HepG2 xenografted mice[5].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Dihydroergotamine (mesylate)
- Cat. No.:
- HY-B0670A
- Quantity:
Your information is safe with us.